CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 128 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2013. The put-call ratio across all filers is 1.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $1,875,000 | -4.4% | 660,230 | -3.7% | 0.01% | -6.7% |
| Q3 2017 | $1,961,000 | +7.9% | 685,730 | -6.8% | 0.02% | -6.2% |
| Q2 2017 | $1,817,000 | -32.6% | 735,630 | -1.5% | 0.02% | -33.3% |
| Q1 2017 | $2,695,000 | -10.6% | 746,530 | -12.3% | 0.02% | -14.3% |
| Q4 2016 | $3,013,000 | -56.0% | 851,030 | -49.8% | 0.03% | -56.9% |
| Q3 2016 | $6,847,000 | +143.8% | 1,694,700 | +165.0% | 0.06% | +160.0% |
| Q2 2016 | $2,808,000 | +87.8% | 639,600 | +61.7% | 0.02% | +56.2% |
| Q1 2016 | $1,495,000 | -15.9% | 395,600 | +248.9% | 0.02% | -15.8% |
| Q4 2015 | $1,778,000 | +70.6% | 113,400 | +174.6% | 0.02% | +58.3% |
| Q2 2015 | $1,042,000 | -27.6% | 41,300 | -47.7% | 0.01% | -36.8% |
| Q4 2014 | $1,440,000 | +228.8% | 78,900 | +181.0% | 0.02% | +111.1% |
| Q2 2013 | $438,000 | – | 28,075 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |